Clinical Trial Update: Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome [Phase 2, Phase 3]

View source ↗

Summary

An update on the planned Phase 2/3 trial evaluating NTI164 for Rett syndrome, noting that recruitment has not yet begun.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rett Syndrome

Drugs mentioned

• NTI164

Snippet

Sponsor: Fenix Innovation Group | Conditions: RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING